Synopsis of recent research by authors named "Zeyang Bai"
- Zeyang Bai's research primarily focuses on the pathogenesis and treatment of pulmonary arterial hypertension (PAH), particularly exploring the roles of specific biomarkers and innovative therapeutic strategies such as microRNA modulation and vaccine development for vascular remodeling in PAH.
- In his studies, Bai identified that the inhibition of microRNA-30a can alleviate vascular remodeling associated with PAH, emphasizing its potential as a therapeutic target in hypoxia-related diseases.
- Bai's work also highlights the long-term benefits of a therapeutic vaccine targeting the endothelin-1 receptor type A, indicating promising results in preventing pulmonary arteriole remodeling without causing significant immune-mediated damage in experimental models.
